- PR Hacker
- TOP B2B
- TOP Creative
- TOP Digital
- TOP Education
- TOP Finance
- TOP Health
- TOP Politics
- TOP Tech
The U.S. biosimilars market is set for major growth via biopharmaceutical companies entering the fray with huge investments in R&D for new biosimilars and personalized therapy for critical diseases. Educating and aligning HCP communities for these new generation drugs will be the major focus for firms in 2019-20.
The biopharma industry is witnessing increased collaboration, sometimes even between firms who would traditionally compete. To thrive in the increasingly competitive modern pharmaceutical market, companies will need to work together to develop innovative new products, services, and solutions.
The New Health Economy is inspiring pharmaceutical companies new ways to manage data, place a value on medical treatments, and deal with empowered patients. Driven by the “Patient first” initiative, pharmaceutical companies are investing in data and analytics to directly engage with the patients.
Pharmaceutical, biotech companies are often challenged by:
Empowered by deep domain understanding and being cognizant of Pharmaceutical and Biotech companies’ regulatory and legal obligations in product promotion, TOP Healthcare team has been helping brands during the entire lifecycle of their product innovation and launch. Our solution is based on designing a long term, holistic marketing program embracing digital, PR & KOL and traditional for each target audience, i.e. HCP, DTC, and payers.
Backed by data science and insights on physicians’ and patients’ journey, we continuously refine strategies and roadmaps based on core philosophy.
Test: We craft multiple marketing tactics, particularly in digital, to test which resonates best with HCP and DTC.
Optimize: We narrow down on what has worked best, and carry our learning for the next rounds of marketing execution.
Perform: We deliver results.